Back to Search Start Over

Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

Authors :
Colombo, N.
Gantzer, J.
Ataseven, B.
Cropet, C.
Scambia, G.
Herrero, A.
Sevelda, P.
Kobayashi, H.
Vuylsteke, Peter
Mirza, Mansoor Raza
Priou, F.
Buderath, Paul
Pisano, C.
Lainez, N.
Guillemet, Cecile
Burges, A.
Sverdlin, R.
El-Balat, A.
Raban, Nadia
Ray-Coquard, Isabelle
Publication Year :
2020

Subjects

Subjects :
Medizin

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.unidue...bib..e832205083dda2219e9e9d2a10c96495

Tools

Authors Abstract Subjects Details